The price of Dongsan Pharmaceuticals fell 7.755 percent to 45.20 yuan, wearing 10 antennas (about 45.74 yuan);
1.69 per cent to 8.74.
East Sunshine Pharmaceuticals' direct controlling shareholder Yichang Dong Sunshine Pharmaceuticals intends to transfer its full equity interest in the company, about 49.91 percent of its domestic equity, to DongsanCo after the 12-month sale period under the listing rules expires regularly. The East Sunshine Section has published on the SSE website the results for the first 10 months of 2017 relating to Dongsan Pharmaceuticals, with a turnover of 1.138 billion yuan (the same as currency), an operating profit of 555 million yuan and a profit attributable to shareholders of the parent company of 471 million yuan.
Sun Medicine's net profit for the period ended June 2017 was 40.4% year-on-year, with a basic profit of 0.67 yuan per share.
the company reported a profit earlier this month and expects full-year net profit for the year to end December, up no less than 70 percent from the same period in 2016. The Group noted that the Group's academic promotion activities continued to improve as a result of a significant increase in sales of its main products. (Sina Hong Kong Stock)